Jeffrey Raizer

Northwestern University

Disclosure: NO DISCLOSURE DATA

Presentation(s):

• ACTR-32 - NRG Oncology RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Vs. Bevacizumab Alone as Treatment for Recurrent Glioblastoma

  Friday, November 22
  2:10 PM – 2:20 PM

• HOUT-11 - Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas

  Friday, November 22
  2:35 PM – 2:40 PM

• ACTR-40 - Phase 2 safety and efficacy of AR-67 (7-t-butyldimethylsiltyl-10-hydroxycamptothecin) in patients with recurrent Glioblastoma Multiforme (GBM) or Gliosarcoma

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-33 - Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

  Saturday, November 23
  5:00 PM – 7:00 PM